Britain’s competition watchdog has accused Merck & Co of operating an unfair discount scheme for its medicine Remicade that it said was designed to restrict competition from so-called biosimilar copies.
The Competition and Markets Authority (CMA) said on Tuesday it had provisionally found that the U.S. company’s European unit, Merck Sharp & Dohme, had abused its dominant position through a discount scheme for Remicade.
Remicade, known generically as infliximab, is an antibody drug used to treat conditions such as rheumatoid arthritis and Crohn’s disease.
